Monovalent XBB.1.5 boosters provided short-term protection against SARS-CoV-2 infection, particularly against moderate symptoms. Vaccine formulations that target the circulating variant may be suitable for inclusion in seasonal vaccination campaigns among HCWs.
The SARS-CoV-2 virus continues to cause substantial morbidity and mortality, particularly during the winter period. The Winter Covid Infection Study (WCIS) ran from the 14th of November 2023 to the 7th of March 2024, and enabled the UK Health Security Agency to publish fortnightly estimates of...
Millions have been affected by long COVID, in which some people struggle to recover from the acute phase of COVID-19, suffering symptoms including tiredness, brain fog and shortness of breath
The study identifies gut microbiome signatures during acute SARS-CoV-2 infection as predictors of long COVID, enhancing understanding of symptom variability.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.